Want to join the conversation?
$BMY CEO Giovanni Caforio said its Hepatitis C portfolio delivered strong performance in 2015, notably in Japan, in certain European countries and most recently in the US, where the company saw good performance in 4Q15. He added that Orencia also had a good year with almost $1.9Bil in sales, 14% increase over 2014.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?